Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Operating Expenses (2020 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Other Operating Expenses data on record, last reported at $453000.0 in Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 332.31% year-over-year to $453000.0; the TTM value through Dec 2025 reached $201.2 million, up 102769.9%, while the annual FY2025 figure was -$1.7 million, 427.71% down from the prior year.
  • Other Operating Expenses reached $453000.0 in Q3 2025 per VRDN's latest filing, down from $106.8 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $106.8 million in Q2 2025 and bottomed at -$195000.0 in Q3 2024.
  • Average Other Operating Expenses over 5 years is $25.5 million, with a median of $8.6 million recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: plummeted 100.93% in 2024, then soared 332.31% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $6.5 million in 2021, then soared by 35.84% to $8.9 million in 2022, then surged by 272.34% to $33.0 million in 2023, then tumbled by 100.0% to -$1000.0 in 2024, then soared by 45400.0% to $453000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $453000.0 in Q3 2025, $106.8 million in Q2 2025, and $93.9 million in Q1 2025.